US FDA approves AbbVie ’s Imbruvica to treat marginal zone lymphoma

The US Food and Drug Administration (FDA) has approved AbbVie ’s Imbruvica (ibrutinib) for the treatment of patients with relapsed / refractory (R/R) marginal zone lymphoma (MZL).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news